Quiet pain relief focus, Salonpas Pain Relieving Patch stays a bestseller

Topical patches instead of pills: Hisamitsu’s Salonpas Pain Relieving Patch remains one of the most visible over-the-counter pain relief products in US drugstores, combining menthol and methyl salicylate in a thin adhesive format for localized muscle and joint pain.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 11:13 AM ET. Details in the imprint.

For shoppers scanning the pain relief aisle for an alternative to pills, Hisamitsu’s Salonpas Pain Relieving Patch remains one of the most prominent over-the-counter options, offering localized relief via thin adhesive patches that can be worn under clothing for hours at a time. The flagship patch in the US lineup combines menthol and methyl salicylate in a hydrogel matrix and is approved by the FDA as an over-the-counter external analgesic patch for relief of minor muscle and joint pain due to strains, sprains, bruises, backache and arthritis, making it a staple in many home medicine cabinets. The official US product page describes the patch as a convenient alternative for people who prefer topical treatment over oral pain relievers.

How the Salonpas Pain Relieving Patch is designed to work

Each Salonpas Pain Relieving Patch uses a flexible non-woven backing coated with a hydrogel layer that contains 6.3 percent menthol and 10 percent methyl salicylate, which deliver a cooling and then warming sensation intended to distract from underlying pain while the active ingredients are absorbed through the skin to act as topical analgesics. A single standard patch measures roughly 2.83 by 4.13 inches, is thin enough to fit comfortably under clothing, and is advertised for up to 8 hours of wear per application, so users can apply it before work or sleep without needing frequent reapplication. According to labeling and US packaging, adults and children 12 years and older are typically instructed to use one patch at a time on the affected area, with a maximum number of patches and total duration of use spelled out on the box for safety. FDA-listed drug information on DailyMed confirms the active ingredients, strengths and recommended usage limits.

Unlike oral nonsteroidal anti-inflammatory drugs, a topical patch is designed to concentrate its effect at the site of application, which may appeal to users concerned about systemic side effects associated with long-term oral pain medication use. The adhesive format also distinguishes Salonpas from creams and gels that can rub off on clothing or require repeated applications throughout the day, as the patch is meant to stay in place during normal movement while gradually releasing its active ingredients. Hisamitsu positions Salonpas as part of a broader portfolio of external pain relief products, including larger patches for the back, lidocaine-based variants and gel patches, allowing consumers to match patch size and active ingredient profile to the type of pain and body area they are treating.

From a retail perspective, the Pain Relieving Patch is widely distributed in US pharmacies, mass retailers and online storefronts, often sold in multi-packs that bring the per-patch cost down for regular users. The product’s packaging emphasizes its status as the first over-the-counter topical analgesic patch approved by the US Food and Drug Administration, a milestone that Hisamitsu often highlights when marketing Salonpas in English-language markets. While exact sales figures for the specific patch are not broken out publicly, Salonpas-branded patches are described in company materials as core drivers of its overseas consumer healthcare business, especially in North America and Asia, where aging populations and active lifestyles support ongoing demand for non-prescription pain relief.

For Hisamitsu as a group, topical pain relief remains the defining business segment, with Salonpas as the flagship brand anchored by this core Pain Relieving Patch and complemented by region-specific variants tailored to local regulations and consumer preferences. In its latest financial communications, management links overseas growth in the Salonpas brand to increased shelf presence in US and Asian drugstores and continued marketing spend around awareness days such as Salonpas Day in May, underscoring how strongly the company’s identity is tied to its patch technology. Hisamitsu’s English-language annual report highlights the Salonpas franchise as a central pillar of its global OTC strategy and a key contributor to international revenue. Shares of Hisamitsu Pharmaceutical Co., Inc. (JP3845000001) are listed on the Tokyo Stock Exchange, where the company’s performance gives investors indirect exposure to the global demand trend for topical pain relief patches such as Salonpas.

Salonpas Pain Relieving Patch in brief

• Product: Salonpas Pain Relieving Patch
• Manufacturer: Hisamitsu Pharmaceutical Co., Inc.
• Category: Flagship/Bestseller topical pain relief patch
• Launch date: Original Salonpas brand introduced in Japan in the 1930s; FDA-approved OTC patch status in the US dates from the late 2000s
• MSRP / Price: Commonly sold in multi-packs in US retail; exact pricing varies by retailer and pack size
• Availability: Widely available in US drugstores, mass-market retailers and online marketplaces, as well as in multiple Asian markets
• Target audience: Adults seeking over-the-counter topical relief for minor muscle and joint pain who prefer patches over oral medication or creams
• Key differentiator / USP: Thin, flexible OTC analgesic patch with menthol and methyl salicylate, designed for up to 8 hours of localized pain relief and backed by decades of brand recognition

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.